Glucagon-like peptide-1 receptor agonists are associated with decreased risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy

被引：0
|
作者：
Tauqeer, Zujaja [1 ]
Bracha, Peter [1 ,2 ]
Hua, Peiying [3 ]
Cui, Qi N. [1 ]
VanderBeek, Brian L. [1 ,4 ]
机构：
[1] Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA USA
[2] Gundersen Hlth Syst, Gundersen Eye Inst, La Crosse, WI USA
[3] Univ Penn, Perelman Sch Med, Ctr Preventat Ophthalmol & Biostat, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, Ctr Pharmacoepidemiol Res & Training, Philadelphia, PA 19104 USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2021年 / 62卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: Safe or not? The ANGIOSAFE type 2 diabetes study
    Julla, J. -B.
    Gaborit, B.
    Massin, P.
    Ancel, P.
    Vidal-Trecan, T.
    Riveline, J. -P.
    Dutour, A.
    Gautier, J. -F.
    DIABETOLOGIA, 2019, 62 : S498 - S498
  • [22] RISK FACTORS THAT AFFECT NON-PROLIFERATIVE DIABETIC RETINOPATHY 2018
    Vaca Orellana, Susan Catherine
    Mederos Molina, Katiuska
    Escariz Borrego, Liliam Iris
    Diaz Rodriguez, Jorge Alberto
    REVISTA SAN GREGORIO, 2019, (29): : 59 - 65
  • [23] Progression to Vision-Threatening Retinopathy Complications Following Panretinal Laser for Proliferative Diabetic Retinopathy
    Muste, Justin C.
    Valentim, Carolina C. S.
    Iyer, Amogh I.
    Mammo, Danny A.
    Alsaloum, Peter
    Xu, Colin M.
    Russell, Matthew W.
    Singh, Rishi P.
    Talcott, Katherine E.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2022, 53 (04): : 186 - +
  • [24] Statin use and the risk of progression to vision threatening diabetic retinopathy
    Meer, Elana
    Bavinger, J. Clay
    Yu, Yinxi
    Hua, Peiying
    McGeehan, Brendan
    VanderBeek, Brian L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 (06) : 652 - 660
  • [25] Glucagon-like Peptide 1 Receptor Agonist use and the effect on diabetic retinopathy: An uncertain relationship
    Hui, Benjamin T. K.
    Yeong, Jian Lee
    Peto, Tunde
    Willoughby, Colin E.
    PEPTIDES, 2024, 178
  • [26] Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy
    Dhanapalaratnam, Roshan
    Issar, Tushar
    Poynten, Ann M.
    Milner, Kerry-Lee
    Kwai, Natalie C. G.
    Krishnan, Arun V.
    JOURNAL OF NEUROPHYSIOLOGY, 2025, 133 (01) : 14 - 21
  • [27] Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients
    Nadeem, Danial
    Taye, Mahdi
    Still, Matthew D.
    Mcshea, Shannon
    Satterfield, Daniel
    Dove, James T.
    Wood, G. Craig
    Addissie, Benyam D.
    Diehl, David L.
    Johal, Amitpal S.
    Khara, Harshit S.
    Confer, Bradley D.
    Still, Christopher D.
    GASTROINTESTINAL ENDOSCOPY, 2024, 100 (04) : 745 - 749
  • [28] Glucagon-Like Peptide-1 Receptor Agonists and Diabetic Cardiovascular Disease: Implications of the LEADER Study
    Swislocki, Arthur L. M.
    Jialal, Ishwarlal
    METABOLIC SYNDROME AND RELATED DISORDERS, 2016, 14 (08) : 375 - 377
  • [29] Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy
    Dauner, Daniel G.
    Farley, Joel F.
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (04) : 475 - 480
  • [30] Impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy: A meta-analysis of clinical studies emphasising retinal changes as a primary outcome
    Kapoor, Ishani
    Sarvepalli, Swara M.
    D'Alessio, David A.
    Hadziahmetovic, Majda
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2025, 53 (01): : 67 - 75
12345